214484-09-0

Basic information

• Product Name: 3-Quinolinecarbonitrile, 4-[(3-bromophenyl)amino]-6-nitro-
• CAS NO: 214484-09-0
• Molecular Formula: C16H9BrN4O2
• Molecular Weight: 369.177
• Mol File: 214484-09-0.mol

Chemical Properties

• CAS DataBase Reference: 3-Quinolinecarbonitrile, 4-[(3-bromophenyl)amino]-6-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Quinolinecarbonitrile, 4-[(3-bromophenyl)amino]-6-nitro-(214484-09-0)
• EPA Substance Registry System: 3-Quinolinecarbonitrile, 4-[(3-bromophenyl)amino]-6-nitro-(214484-09-0)

Safety Data

• Hazardous Substances Data: 214484-09-0(Hazardous Substances Data)

Upstream product

• 591-19-5 m-Bromoaniline 
• 214470-37-8 4-chloro-6-nitro-3-quinolinecarbonitrile 
• 57338-24-6 (E)-ethyl 2-cyano-3-((4-nitrophenyl)amino)acrylate 
• 2305-65-9 4-hydroxy-6-nitroquinoline-3-carbonitrile 
• 100-01-6 4-nitro-aniline 
• 2458-24-4 2-cyano-3-(4-nitro-phenylamino)-acrylic acid ethyl ester 
• 214470-35-6 6-nitro-4-oxo-1,4-dihydro-quinoline-3-carbonitrile 

Downstream Products

• 214484-72-7 4-diethylamino-but-2-enoic acid [4-(3-bromophenylamino)-3-cyano-quinolin-6-yl]-amide 
• 214484-73-8 4-methylamino-but-2-enoic acid [4-(3-bromophenylamino)-3-cyano-quinolin-6-yl]-amide 
• 214484-71-6 4-dimethylamino-but-2-enoic acid [4-(3-bromophenylamino)-3-cyano-quinolin-6-yl]-amide 
• 214484-53-4 4-methoxy-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide 
• 214484-70-5 4-bromo-but-2-enoic acid [4-(3-bromo-phenylamino)-3-cyano-quinolin-6-yl]-amide 
• 214485-45-7 N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinolinyl]-4-(N-ethylpiperazino)-2-butynamide 
• 214485-47-9 N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinolinyl]-4-(n-methylpiperazino)-2-butynamide 
• 214486-65-4 N-[4-[(3-Bromophenyl)amino]-3-cyano-6-quinolinyl]-4-(tert-butyl-dimethyl-silanyloxy)-2-butynamide 
• 214484-11-4 6-amino-4-[(3-bromophenyl)-amino]-3-quinolinecarbonitrile 

Relevant articles and documents

Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

This invention provides compounds of formula 1 wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula (1); wherein R1, R2, R3, R4, X, Y, and n are defined hereinbefore, or a pharmaceutically acceptable salt thereof.

SUBSTITUTED 3-CYANO QUINOLINES

This invention provides compounds having formula (1), wherein: X is cycloalkyl which may be optionally substituted; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally substituted; n is 0-1; Y is -NH-, -O-, -S-, or -NR-; R is alkyl of 1-6 carbon atoms; R1, R2, R3 and R4 are each, independently, hydrogen, halogen, alkyl, alkenyl, alkynyl, alkenyloxy, alkynyloxy, hydroxymethyl, halomethyl, alkanoyloxy, alkenoyloxy, alkynoyloxy, alkanoyloxymethyl, alkenoyloxymethyl, alkynoyloxymethyl, alkoxymethyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulfonamido, alkenylsulfonamido, alkynylsulfonamido, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy, carboalkyl, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino, alkylamino, dialkylamino, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, phenylamino, benzylamino, formulae (a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p, q or r); R5 is alkyl which may be optionally substituted, or phenyl which may be optionally substituted; R6 is hydrogen, alkyl, or alkenyl; R7 is chloro or bromo; R8 is hydrogen, alkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-cycloalkylaminoalkyl, N-cycloalkyl-N-alkylaminoalkyl, N,N-dicycloalkylaminoalkyl, morpholino-N-alkyl, piperidino-N-alkyl, N-alkyl-piperidino-N-alkyl, azacycloalkyl-N-alkyl, hydroxyalkyl, alkoxyalkyl, carboxy, carboalkoxy, phenyl, carboalkyl +, chloro, fluoro, or bromo; Z is amino, hydroxy, alkoxy, alkylamino, dialkylamino, morpholino, piperazino, N-alkylpiperazino, or pyrrolidino; m = 1-4, q = 1-3, and p = 0-3; any of the substituents R1, R2, R3 or R4 that are located on contiguous carbon atoms can together be the divalent radical -O-C(R8)2-O-; or a pharmaceutically acceptable salt thereof with the proviso that when Y is -NH-, R1, R2, R3 and R4 are hydrogen, and n is O, X is not 2-methylphenyl, which are inhibitors of protein tyrosine kinase.

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epi

A series of of 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile derivatives that function as irreversible inhibitors of EGFR and HER-2 kinases have been prepared. These inhibitors have, at the 6-position, butynamide, crotonamide, and methacrylamide Mic

Method of treating or inhibiting colonic polyps

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula 1 wherein:R1, R2, R3, R4, X, Y, and n are as defined hereinbefore, or a pharmaceutically acceptable salt thereof.

Substituted 3-cyanoquinolines

This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.